Here’s the uncomfortable truth: validating an AI model once is like approving a drug that reformulates itself overnight. Model risk management is forcing pharma to confront this.
3 years ago, AI was a pilot project in pharma.
Today, it’s everywhere — and risk is scaling faster than governance.
The quiet winner holding it all together? Enterprise Risk Management.
Here’s the uncomfortable truth:
Pharma doesn’t trust most AI vendors.
And without bias controls, audit trails, and transparency, they never will.
Ethical AI is now the price of entry.
85% of pharma leaders want AI scale-up — but almost none have the talent required to make it safe.
Most pharma teams are still trying to force AI into 20‑year‑old GxP processes — but the playbook they need already exists, and it didn’t come from EMA or FDA.
A pharma VP told me the moment everything changed: ‘We thought we knew our customers—until our data finally started talking to each other.’ What happened next shocked the entire team…
